Ongoing Clinical Trials at SanBio, Inc.

100 %
0 %
Information about Ongoing Clinical Trials at SanBio, Inc.
Health & Medicine

Published on October 13, 2014

Author: BrianFrenzel

Source: slideshare.net

Description

The president and chief executive officer of Tosk, Inc., Brian Frenzel oversees a company that creates drugs that reduce the side effects of prescription medications. Moreover, Brian Frenzel also serves as a director at the biotechnology firm, SanBio, Inc.

1.  The president and chief executive officer of Tosk, Inc., Brian Frenzel oversees a company that creates drugs that reduce the side effects of prescription medications. Moreover, Brian Frenzel also serves as a director at the biotechnology firm, SanBio, Inc. Headquartered in Mountain View, California, SanBio discovers and develops therapies for patients suffering from neurodegenerative diseases. The firm has recently completed Phase 1/2a human clinical trials for its SB623 cell therapy for patients suffering disability as a result of ischemic stroke.

2.  The studies were conducted at Stanford University Medical Center in Palo Alto, California and the University of Pittsburgh medical center in Pittsburgh, Pennsylvania. The subjects in the study were 18 chronic and stable patients who had an ischemic stroke between six months and five years prior to SB623 treatment. Researchers delivered three doses of the medication in an open-label, staggered escalation paradigm. The primary objective of the study was to demonstrate the safety of the pharmaceutical product.

3.  Operating under a two-year time frame, SanBio used periodic MRIs and measured humoral and cell-mediated immunological function to test the drug against FDA and WHO safety criteria. The study’s secondary goal was to observe improvement in motor, sensory, and cognitive ability following stroke. These results were analyzed based on the European and National Institutes of Health Stroke Scales and Modified Rankin Score. The company also used FDG-PET scans to test for changes in brain metabolism.

Add a comment

Related presentations

Related pages

SanBio Announces the First Public Presentation of Data ...

SanBio Announces the First Public Presentation of Data from its On-going Human Clinical ... SOURCE SanBio Inc. ... Clinical Trials & Medical Discoveries ...
Read more

A Study of Modified Stem Cells in Stable Ischemic Stroke ...

This study is ongoing, ... The primary purpose of the clinical study is to determine the safety of a modified stem ... SanBio, Inc. ClinicalTrials.gov ...
Read more

Mesenchymal Stromal Cells to Treat Brain Injury - SanBio

Mesenchymal Stromal Cells to Treat Brain Injury ... SanBio, Inc., Mountain View, California USA 1. ... there are 11 ongoing clinical trials worldwide using
Read more

A Study of Modified Stem Cells in Stable Ischemic Stroke ...

A Study of Modified Stem Cells in Stable Ischemic Stroke. ... SanBio, Inc. Information provided by (Responsible Party): SanBio ... This study is ongoing, ...
Read more

SanBio Publishes Interim 12-Month Phase 1/2a Clinical ...

SanBio, Inc., a scientific leader in regenerative medicine for neurological disorders, today announced the publication of an important paper in ...
Read more

TRANSPLANTED MESENCHYMAL STEM CELLS AID ... - SanBio — Home

Transplanted Mesenchymal Stem Cells Aid the Injured Brain through Trophic Support ... failed in clinical trials ... ongoing clinical trials ...
Read more

Alpha Stem Cell Clinics Trials | California's Stem Cell Agency

... high quality clinical trials. Browse the list of ongoing trials at ... Alpha Stem Cell Clinics Network is ... SanBio Inc. Traumatic ...
Read more

Clinical Trials: Intracerebral Cell Therapy in Stroke ...

... (SanBio, Inc., ... Inc., Gilroy, CA) ... so too will translation to the clinical realm. Ongoing trials, such as with SB623 cells, ...
Read more

Top 10 Ccra profiles in San Francisco Bay Area | LinkedIn

Global Director of Clinical Operations at SanBio: ... of multiple ongoing clinical trials. ... at BioMarin Pharmaceutical Inc., Clinical Trial ...
Read more